Followers | 13 |
Posts | 1547 |
Boards Moderated | 0 |
Alias Born | 06/14/2018 |
Monday, November 20, 2023 6:00:28 PM
But back to MRKR, Let's leave aside bio technologies like RNAI and MRNA and CRISPR (which are all genetically engineered and have all had severe side effect problems including patient deaths) and just compare CAR-T to MRKR's Mulit-TAA, it is hard not to see the advantage of Multi-TAA (Tumor Associated Antigens).
CAR-T (chimeric antigen receptor -T cell therapy) is ALSO genetically engineered.
Has had many problems with Cytokine release syndrome (BAD).
Has killed patients (WORSE than BAD).
Only targets one antigen.
Costs much more and takes much longer to produce.
Multi-TAA is NOT genetically engineered.
Has had NO problems with Cytokine release syndrome or patient deaths.
Targets Multi antigens for each specific cancer indication.
Induces Epitope spreading (the body creates other antigens to target the cancer naturally besides those that were introduced).
Costs much less and much quicker to produce.
Has had success so far in Phase 1 and Phase 2 trials.
MRKR, IF IF IF everything goes according to plan, will pay off big in the second half of 2024 and in 2025.
By the summer of 2024, we should have a decent amount of trial data on AML and Lymphoma.
Also working on Panceatic (a ways off and a much tougher cancer to crack).
As we discussed on the other IHUB board, when you buy them when they are small and hold them, an up 10,000% is not out of the question.
VRTX, SGEN,EXEL,ALNY, ARWR, PCYC (bought by AbbVie), all went from small to many Billions in market cap for me.
But as you never really know when good news will come out, you just have to buy and hold, but for MRKR, it should be an end of 2024/2025 big payoff.
Another much closer payoff is IOVA who is working on TIL technology. TIL - tumor infiltrating lymphocyte therapy.
We are waiting for final data and FDA approval in Feb. 2024.
BIG payoff IF IF IF. Gilead might just buy them out.
Speaking of Gilead, MRKR has a sister company, Allovir, ALVR (same founders) that Gilead own a giant chunk of.
I know that you are a bond and dividend guy, but check all 3 of them out, you may want to take a small flyer position on 1 or 2 or all 3 of them.
Good Luck.
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM